Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.32

+1.4%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.09B
EPS-0.5300
P/E Ratio-10.05
Earnings Date08/06/2026

svra

Net Cash Provided by Investing Activities

Last Annual Value

-18.44M

3-Year CAGR

-11%

5-Year CAGR

-25%

10-Year CAGR

-20%

Savara Inc.

Savara Inc. Competitors Analysis of Net Cash Provided by Investing Activities

SVRA · NASDAQ
CompanyNet Cash Provided by Investing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
-18.44M
N/AN/AN/A 
-13.10M
N/AN/AN/A
107.25M
N/A8.3%28.5%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
-14.54M
N/AN/AN/A
-318.45M
N/AN/AN/A
-40.87M
N/AN/AN/A
72.46M
N/AN/AN/A
68.58M
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
103.97M
N/AN/AN/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.3249, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.3249